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The application of lung volume reduction surgery in clinical practice is limited by high postoperative morbidity and stringent
selection criteria. This has been the impetus for the development of bronchoscopic approaches to lung volume reduction. A range
of diﬀerent techniques such as endobronchial blockers, airway bypass, endobronchial valves, thermal vapor ablation, biological
sealants, and airway implants have been employed on both homogeneous as well as heterogeneous emphysema. The currently
available data on eﬃcacy of bronchoscopic lung volume reduction are not conclusive and subjective beneﬁt in dyspnoea scores
is a more frequent ﬁnding than improvements on spirometry or exercise tolerance. Safety data are more promising with rare
procedure-related mortality, few serious complications, and short hospital length of stay. The ﬁeld of bronchoscopic lung volume
reduction continues to evolve as ongoing prospective randomized trials build on earlier feasibility data to clarify the true eﬃcacy
of such techniques.
1.Introduction
Bronchoscopic techniques for the management of emphy-
sema have evolved from the success of surgical treatment.
Lung volume reduction surgery involves the removal of 20%
to 30% of each lung and targets the most emphysematous
segments. Patients with heterogeneous upper lobe emphy-
sema and a low baseline exercise capacity have been identi-
ﬁed as a subgroup within Chronic Obstructive Pulmonary
Disease (COPD), in whom even mortality beneﬁts can be
achieved along with improvements in exercise capacity and
qualityof life [1]. This subgroupexcludespatientswith FEV1
and diﬀusion capacity <20% because of high surgical risks.
Air trapping and neuromechanical dissociation, that is,
the disparity between eﬀort and ventilatory output, are the
mechanistic links that are being targeted by lung volume
reduction [2]. Both airway narrowing and loss of elastic
recoil cause expiratory air ﬂow limitation in COPD. During
exercise, any increase in respiratory rate shortens expiratory
time and can result in air trapping. This air trapping
reducesinspiratorycapacityandlimitsventilation.Asaresult
of the restriction on inspiratory capacity, any increase in
minute ventilation can then only be achieved by increasing
respiratory rate further that in turn results in a vicious cycle
of more dynamic air trapping.
Lung volume reduction attempts to correct loss of elastic
recoil by reducing the volume of the most damaged lung
segments and allowing the remaining less damaged tissues to
resize. By eliminating parts of emphysematous lung with the
longest expiratory time constants and removing dead space,
dynamic air trapping is reduced and exercise capacity can be
increased. The operating length of respiratory musclesis also
normalized by restoring the normal dimensions of both the
chest wall and the diaphragm.
Increased short-term mortality of approximately 5% and
postoperative morbidity are major limitations of surgical
lung volume reduction [1] .T h er e p o r t e dr a t eo fi n t r a o p e r -
ative complications is 9% and postoperative complications
is 58.7% with elevated risks for reintubation (21.8%),
arrthymias (18.6%),pneumonia(18.2%),readmission tothe
intensive care unit (11.7%),and tracheotomy (8.2%) [3]. Air
leaks of a median duration of 7 days have also been reported
in up to 90% of patients [4]. In the National Emphysema
Treatment Trial (NETT) study, up to 28% of patients2 Pulmonary Medicine
were hospitalized or living in a nursing home/rehabilitation
facility at 1 month after surgery [1]. Unfortunately, the
price of all this postoperative morbidity and mortality does
not guarantee beneﬁts. Only 30% of patients in the most
favorable subgroup of COPD with upper lobe disease and
low baseline exercise tolerance derived a clinically signiﬁcant
improvement in exercise capacity of more than 10 watts
and 48% registered a greater than 8-point decrease in
the St. George’s Respiratory Questionnaire at 24 months
[1].
The extremely restrictive selection criteria coupled with
the relatively high morbidity have been the likely reasons
for the decrease in patients undergoing surgical lung vol-
ume reduction since the publication of the NETT data
[5]. This situation persists in the United States despite
established criteria for Medicare coverage of surgery. These
factors have been the incentive for developing less invasive
endoscopic modalities. Bronchoscopic lung volume reduc-
tion has pursued various approaches using a range of
modalities such as blockers, stents, valves, thermal vapor
ablation, sealants, and implants (Table 1). The physiological
basis of each modality is not identical and in some cases
distinct from conventional lung volume reduction surgery.
The ideal indications also diﬀer with airway bypass stents
targetinghomogenousemphysema,while valvesandthermal
vapor ablation target heterogeneous emphysema. Biological
sealants and endoscopiccoilimplants havebeen used in both
homogenous and heterogeneous emphysema.
2.EndobronchialBlockers
Endobronchial blockers aﬀect resorption atelectasis by
occludingairways leading to emphysematous lung segments.
Initially silicone vascular balloons ﬁlled with radio opaque
contrast were inserted before the advent of custom-built
stainless steel stents with a central occlusive sponge [6].
However, the high rate of endobronchial blocker migration,
postobstructive pneumonia, and the need for repeat endo-
scopic procedures have limited further development of this
technique [6].
3.AirwayBypassStents
Airway bypass involves the creation of extra-anatomic
bronchial fenestrations to deﬂate emphysematous lung
parenchyma. This technique relies on the presence of
collateral ventilation which is the ventilation of alveoli
through anatomic channels that bypass the airways. These
channels include interalveolar pores, accessory bronchiole-
alveolar connections, accessory respiratory bronchioles, and
interlobar pathways across ﬁssures [7]. Although collateral
ventilation plays an insigniﬁcant role in normal lungs, in
emphysema where there is increased airﬂow resistance,
severely obstructed lung segments are ventilated by these
channels. The degree of collateral ventilation may also
correlate with the extent of homogeneity of emphysema [8].
Inendoscopicairwaybypass,thenewlycreatedlowresistance
bronchial fenestrations allow trapped air to escape by
bypassing high resistance obstructed airways. Distal emphy-
sematous lung segments are drained via collateral ventilation
throughthesefenestrations andlungcomplianceisimproved
by reductions in dead space [9]. This improvement in lung
compliance occurs without any actual change in pulmonary
elastic properties. Instead inspiratory capacity available
for gas exchange is increased by reduction in air trapping
[10].
Current airway bypass procedures are performed on
patients with homogenous emphysema. There are 3 steps
that are performed via ﬂexible bronchoscopy: identiﬁcation
of an area of the segmental bronchi that is free from blood
vessels using a Doppler probe, fenestration of the airways,
and placement of a paclitaxel eluting stent. Paclitaxel is
a mitotic inhibitor that prevents granulation tissue from
obstructing the stent.
The current published data on airway bypass is a multi-
center, open labeled study on 35 patients with homogenous
emphysema who had bypass stentsplaced in both lungs [11].
A median of 8 stents with a range of 2 to 12 were inserted
[11]. Eﬃcacy data at 6 months was limited. Mean residual
volume was reduced by 400ml and dyspnoea as measured
on a modiﬁed Medical Research Council scale dropped by
0.5 points [11]. No signiﬁcant changes were recorded on
spirometry, 6-minute walk, and St. George’s Respiratory
Questionnaire.
One death from hemoptysis has been reported with
airway bypass procedures [11]. Data and safety monitoring
board review of the fatal hemoptysis had the following
recommendations which were incorporated into subsequent
procedures: placement of an endobronchial balloon blocker
in the main bronchus as well as Doppler rescanning
between fenestration creation and stent deployment. Failure
to implant stents is another possible intraoperative problem
because of either excessive peribronchial blood vessels or
markedly increased airway wall thickness [11]. Postproce-
dure complications occurred in 59% of cases with COPD
exacerbation in 32%, pneumomediastinum in 5% and
respiratory infection in 27% [11]. At followup bronchoscopy
6 months later, 69% of stents remained patent. Granulation
tissue, radial traction by the surrounding airways and
secretions have been identiﬁed as possible causes of stent
occlusion [12].
4.EndobronchialValves
Endobronchial valves are designed to exclude the worst
aﬀected emphysematous regions from ventilation and con-
sequently reduce dynamic air trapping. If segmental or lobar
resorption atelectasis can be induced, a physiological eﬀect
similar to surgical lung volume reduction is also expected.
Therefore, patients with heterogeneous emphysema are ideal
candidatesforendobronchialvalvetherapy.Valvesallowone-
way ﬂow of secretions and air out of an occluded pulmonary
segment duringexpirationbutpreventany distalﬂow during
inspiration [13]. Currently 2 diﬀerent endobronchial valve
designs are being studied: duckbill and umbrella-shaped
valves.Pulmonary Medicine 3
Table 1: Bronchoscopiclung volume reduction modalities with their indications and commonlyencountered complications.
Bronchoscopic lung volume
reduction modality Indications Commoncomplications
Endobronchial blockers Heterogeneous Emphysema (1) Blocker migration
(2) Postobstructive pneumonia
Airway bypass stents Homogenous Emphysema
(1) COPD exacerbation
(2) Pneumonia/bronchitis
(3) Air leak/pneumomediastinum
Endobronchial valves Heterogeneous Emphysema
(1) COPD exacerbation
(2) Pneumothorax
(3) Bleeding
(4) Pneumonia
Thermal vapor ablation Heterogeneous Emphysema (1) COPD exacerbation
(2) Pneumonitis
Biologicalsealants Both homogenous and
heterogeneous emphysema
(1) COPD exacerbation
(2) Pneumonia/aspiration
Airway implants/coils Both homogenous and
heterogeneous emphysema Data not yet available
The duckbill valves are supported by a nitinol self-
expanding, tubular mesh that is covered with a silicone
membranetoformasealbetweenthevalveandthebronchial
wall. One-way exit of distal air and mucous is facilitated
by the central duckbill. The valves are mounted on to
a loading catheter and deployed via the working channel
of a ﬂexible bronchoscope. Deployment involves 2 stages:
an endoscopic measurement gauge is used to size the
bronchial diameter before a valve of the equivalent size
is chosen. The loading catheter with the chosen valve is
advanced to the target airway and the valve is deployed
by using an actuation handle. A perfectly positioned
endobronchial valve can be visualized on bronchoscopy
with the proximal edge sitting ﬂush with the carina of
the segmental bifurcation. There is now emerging case
report data on silicone duckbill valves that are inserted via
rigid bronchoscopy [14]. These valves are easy to insert
or remove and obviate the need for any special loading
catheters.
Umbrella-shaped valves have a nitinol framework com-
prising 6 support struts. These struts are covered by a
polyurethane membrane that seals the airways. Air and
mucous can escape proximally around the edges of the
membrane but distal ﬂow is limited. A central rod enables
removal or repositioning of the valve. After the airway oriﬁce
is sized with a calibrated water-ﬁlled balloon, these valves are
deployed via a catheter loader through the working channel
of a ﬂexible bronchoscope.
The eﬃcacy data for endobronchial valve therapy are
inconclusive because all published studies have been open
labeled trials with no control arms and have relatively short
3 to 6 month followup. Current data on endobronchial
valves describe procedures that have been performed in one
or both lungs with the intent of either lobar or nonlobar
exclusion. Furthermore, there is a wide variation in number
of valves (4–11) deployed [13, 15–17]. These variables
confound eﬃcacy comparisons between valves and make
it nearly impossible to combine data. Nevertheless, in all
studies the physiological measures of improvements have
been limited. Despite being the most studied bronchoscopic
lung volume reduction technique, patient numbers are still
relatively small (n = 127 for duckbill valves and n = 98
for umbrella-shaped valves in the published literature up
till the publication of the VENT study) [13, 15, 16, 18].
Large standard deviations have also led many investigators
to report data as minimal clinically signiﬁcant diﬀerences,
that is, >15% as compared to preprocedure levels. Such
diﬀerences in FEV1 were observed in 18 to 46% of patients
at 3 months. On 6-minute-walk testing 11% to 55% had a
minimal clinically signiﬁcant diﬀerence after endobronchial
valve therapy [13, 15, 19]. The reported improvements in
subjective parameters such as dyspnoea and quality of life
have been more impressive. Up to 85% of patientsreported a
marked improvement in dyspnoea at 30 days and signiﬁcant
improvements on the St.George’s Respiratory Questionnaire
is a frequent ﬁnding [16, 19–21]. Whether endobronchial
valvetherapyshouldtargetbothlungslikesurgeryorjustone
lung remains controversial. The duckbill valve data suggest
that unilateral therapy is better while the umbrella-shaped
valve data favor bilateral treatment [13, 16, 22]. The reason
for this conﬂicting ﬁnding remains unknown and is a subject
of continued research.
Lobar atelectasis was not achieved in the majority of
patientsevenwith alobarexclusionapproach whereby allthe
bronchitoatargetlobewereoccludedwithvalves[20,21].In
most series, less than 25% of cases reported lobar atelectasis
[13, 15, 23]. Incompleteness of ﬁssures between lobes of
the lung and collateral ventilation accounts for this ﬁnding.
However, the greatest beneﬁts appear to be found in patients
who actually do develop such target lobe atelectasis because
of favorable changes in chest wall dimensions [18, 24].
Endobronchialapproachestomeasure resistance ofcollateral4 Pulmonary Medicine
ventilation have been developed by using pressure mea-
surements in balloon occluded lung segments [18]. Patients
who developed atelectasis recorded collateral ventilation
resistance of several orders of magnitude higher than those
who did not. This suggests that endobronchial collateral
ventilation assessment can accurately identify patients who
will develop atelectasis after endobronchial valve therapy
[18]. Future, bronchoscopic lung volume reduction studies
may need to incorporate such assessment techniques to
preferentially select patients with high collateral ventilation
resistance astheyaremorelikelytoreapgreaterbeneﬁtsfrom
treatment.
The symptomatic beneﬁts that have been observed with
endobronchial valves may be explained by other physiologi-
cal mechanisms as well [22, 25]. By occluding airways, valves
increase resistance to airﬂow such that air is diverted toother
relatively less emphysematous parts of the lung resulting in
reducedairtrapping [25, 26].By excludingthe most diseased
partsofthe lungfrom ventilation,physiological deadspace is
reduced even in the absence of any atelectasis [25].
Current evidence suggests that endobronchial valve
therapy is safer than surgical lung volume reduction. The
only death directly attributable to endobronchial valve
placement was due to postobstructive pneumonia [13].
Hospital length of stay has been short with the majority
of patients discharged within 2 to 4 days [13, 15, 17, 19,
23]. Commonly reported postprocedure complications are
COPD exacerbations (5% to 20%) and pneumothorax (7%
to 11%) [13, 15, 19, 23, 25]. There appears to be a positive
association between the developmentof lobar atelectasis and
pneumothorax occurrence [16]. Pleural adhesions, rapidly
expanding bullae in nontargeted lobes and an ex vacuo
phenomenon may account for this [16, 25]. Targeting
the lingular segment during left upper lobe therapy also
appears to increase the risk of left-sided pneumothoraces
[16]. Despite the single reported mortality, the frequency of
postobstructive pneumonia is rare.
The technical challenges facing endsocopists include
diﬃculty of placement of endobronchial valves in segmental
bronchi of the upper lobes. If moderate sedation is used
instead of general anesthesia, respiratory movements and
cough can impede accurate placement and adjustment
[13, 19]. Proximal hyperplastic granulation tissue has also
been observed on followup bronchoscopy. This granulation
tissue may occlude the valves and prevent future removal
should the need arise [15, 19]. Incidentally, endobronchial
valves have found an unrelated therapeutic indication in
the management of persistent pulmonary air leaks and
have managed to aﬀect either resolution or reduction in
pneumothorax in >90% of cases [27].
5.ThermalVaporAblation
Controlled doses of steam, when delivered to a segmental
airway, can produce an inﬂammatory response that results
in lung volume reduction. The advantage of this technique
is that no prosthesis needs to be inserted. The degree of col-
lateral ventilation is also not an issue because the treatment
works at the level of the lung parenchyma. A nonreusable
2mm vapor catheter is inserted via ﬂexible bronchoscopy to
the target airways. On the vapor catheter, there is a distal
occlusion balloon that isolates the lung segment. A precise
dose of steam generated by an electronically controlled
pressure vessel is then delivered to the isolated airways [28].
In a safety and feasibility trial, 11 patients with hetero-
geneous emphysema were treated unilaterally with a dose of
5 calories per gram of lung tissue [28]. Lung tissue weight
was estimated from CT volume and density analysis. There
were no recorded improvements in spirometry but mean
St. George’s Respiratory Questionnaire scores dropped 15.3
units from 64.4 to 49.1 over 6 months. Adverse events
includedCOPD exacerbations in 4 patients and 2 episodes of
pneumonitis [28]. Given this proof of concept, eﬃcacy and
safety data are now being sought.
6.Biological LungVolumeReduction
Biological agents aim to reduce lung volume by sealing oﬀ
the most emphysematous areas. The rapidly polymerizing
sealant is designed to work at the alveolar level rather than
in the airways. The mechanism of action involves resorp-
tion atelectasis from airway occlusion, subsequent airspace
inﬂammation, and then remodeling. This remodeling will
lead to scarring-induced contraction of lung parenchyma,
and functional lung volume reduction can be expected
within 6 to 8 weeks [29]. The sealant causes blockage
of interalveolar as well as bronchiolar-alveolar collateral
channels and negates the eﬀectsofcollateral ventilation. This
technology aims to achieve beneﬁts by actual reductions in
dead space that is physiologically similar to surgery [30].
After identifying a target region, the distal airways in this
segment are collapsed by wedging the ﬂexible bronchoscope
in the bronchial oriﬁce and applying suction. Initially, 10ml
of a primer (5000U porcine trypsin) is instilled via the
bronchoscope working channel to deactivate surfactant and
promote detachment of epithelial cells [30]. After 2 minutes,
the primer is suctioned out and then 10ml of a cell culture
media is used forwash out.A dual-lumencatheteris inserted
throughtheworking channel andadvanced towithin 2cmof
the distal end of the bronchoscope. A ﬁbrinogen suspension
andthrombin solutionaretheninstilled simultaneously such
that they are mixed in the lumen of the airways distal to
the catheter tip. Then 60ml of air is injected through the
bronchoscope working channel to push the reagents distally.
As the ﬁbrinogen and thrombin mix, they polymerize into a
hydogel within 30 seconds [29].
Bilateral therapy was instituted in 50 patients with upper
lobe predominant emphysema in a phase 2 multicenter trial
[31]. Eight bronchopulmonary subsegments were occluded
in either a single endoscopic session or in a staged manner.
Serious adverse events were documented in 4 patients
due to aspiration, pneumonia, pulmonary embolism, and
a fall related to analgesia. However, there were no doc-
umented fatalities. Procedure-related COPD exacerbations
were observed in 22%. Postoperative leucocytosis, fever, or
malaise occurred in 89% over ﬁrst 24 hours [31].Pulmonary Medicine 5
The primary endpoint of a signiﬁcant reduction in
RV/TLC at 3 months was met [31]. This reduction was
sustainedat6monthsinonlythepatientsreceivinghighdose
therapy(20mlpersubsegmentcomparedto10ml).Minimal
clinically important diﬀerences at 6 months were also
identiﬁed in both groups in FEV1 (38% to 44%); 6-minute
walk (27%), and St. George’s Respiratory Questionnaire
(32% to 46%). Spirometric improvements and radiological
evidence of remodeling were greater in patients who received
high dose treatment [31].
Similar eﬃcacy ﬁndings and safety proﬁle were found in
25 patients with homogenous emphysema in a subsequent
study [32]. However, despite having homogeneous emphy-
sema, these patientshad poorerperfusion toeitherthe upper
lobes or the apical segments of the lower lobes as evidenced
by quantitative scintigraphy scanning. Predictably, the most
damaged lobes identiﬁed by CT scanning that also had the
poorest perfusion were targeted. Again the 20ml high dose
therapy had better eﬃcacy results without any increase in
complications.
Biological lung volume reduction appears safe and a
dose-dependent response has been identiﬁed. In order to
achieve the 20%–30% of lung volume that is removed in
surgery, up to 12 subsegments may need to be sealed in
future eﬃcacy studies [30]. Unlike endobronchial valves,
this therapy is not easily reversible and long-term followup
data is critical. There are also concerns that atelectasis
may diminish with time because of biodegradation of
the hydrogel [26]. An interesting parallel development has
been the bronchoscopic injection of autologous blood and
ﬁbrinogen into an emphysematous bulla to aﬀect similar
volume reduction [33].
7.AirwayImplants
Airway implants such as nitinol coils of 10 to 20cm in
length have been designed for use in patients with either
homogeneousorheterogeneousemphysema.These implants
which are straight when housed in a delivery catheter,
coil up on deployment and tether the lung. The coils are
inserted under ﬂuoroscopic guidance with each insertion
taking less than 2 minutes. Preliminary safety data on 11
patients have shown no evidence of pneumothorax or severe
adverse events [34]. Maximal reduction in lung volume
occurred between 2 to 4 weeks after implantation and there
is some suggestion of improvements in spirometry, exercise
capacity, and quality of life [34]. The trend was for greater
improvement in patients with heterogeneous emphysema
[34]. Despite these promising results, concerns remain that
the coils by distorting bronchi will cause bronchiectasis
and by kinking pulmonary vessels will cause pulmonary
infarcts. This technique remains very much in its infancy of
development.
8.Conclusion
Bronchoscopic lung volume reduction appears to be safer
than surgery and this enhanced safety proﬁle presents an
attractive alternative to COPD patients who are physio-
logically fragile. Eﬃcacy data in the form of short-term,
subjective improvement in dyspnoea and quality of life
are readily available from small, nonrandomized studies.
In contrast, minimal clinically important diﬀerences in
objective endpoints such as spirometry and exercise capacity
have not been a consistent ﬁnding. Reﬁning patient selection
toidentifyoptimalcandidatesforeachindividualendoscopic
modality is likely to improve outcomes in future. It is also
hoped that the ongoing, larger randomized controlled trials
will separate the therapeutic eﬀect from the placebo eﬀect of
these procedures.
The VENT study was published at the time of this paper.
This study randomized 220 patients with heterogeneous
emphysema to receive duckbillendobronchialvalves and 101
patients to standard medical care. At 6 months, there was
a6 % - 7 %d i ﬀerence in FEV1 and 6-minute walk in favor of
bronchoscopic lung volume reduction. However, short-term
morbidity at 90 days was identiﬁed in the intervention arm
with increases in COPD exacerbations and hemoptysis [35].
Patients and physicians will have to decide if this tradeoﬀ
is worthwhile whilst endoscopic techniques continue to be
improved.
Although, bronchoscopic lung volume reduction still
remains experimental and its beneﬁts unproven, the data
that is emerging holds much promise. Perhaps in future,
theseendoscopicmodalitiescanevenbeusedincombination
with endobronchial valves targeting disease in heteroge-
neously diseased upper lobes while airway bypass reducing
hyperinﬂation in more homogenously aﬀected lower lobes
[11]. Bronchoscopic therapy can also help wean patients oﬀ
ventilators and may serve as a bridge to surgery or lung
transplant [36]. The evolution of these ingenious techniques
coupled with the accumulating clinical experience aim to
improve endoscopic technology such that the majority of
patients with severe COPD can soon be oﬀered eﬃcacious
therapeutic options with far less risk of complications.
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